ASNC Issues Statement on How to Use HMDP in Cardiac Amyloidosis Imaging

Shortages of pyrophosphate used to prepare 99mTc-PYP, the radiopharmaceutical most commonly used in the U.S. for noninvasive diagnosis of transthyretin (ATTR) cardiac amyloidosis, should not delay imaging in at-risk patients. Instead, ASNC is guiding imagers to use 99mtechnetium (99mTc)-hydroxymethylene diphosphonate (HMDP or HDP) to ensure patients continue receiving prompt evaluation of, and treatment for, cardiac amyloidosis.

View Resource